<unk> (Onivyde) is a topoisomerase inhibitor that is FDA approved for the treatment of patients with metastatic adenocarcinoma of the pancreas (in combination with fluorouracil and leucovorin) after disease progression following gemcitabine-based therapy.. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include diarrhea, fatigue/asthenia, vomiting, nausea, decreased appetite, stomatitis, and pyrexia (≥ 20%)..
Irinotecan hydrochloride 
Vincristine sulfate
Idoxuridine
Doxorubicin hydrochloride
Trifluridine
Floxuridine
Idarubicin hydrochloride
Epirubicin hydrochloride